Loading...

Bayer AG
XETRA:BAYN

Watchlist Manager
Bayer AG Logo
Bayer AG
XETRA:BAYN
Watchlist
Price: 58.19 EUR +2.66% Market Closed
Updated: Feb 6, 2023

Intrinsic Value

The intrinsic value of one BAYN stock under the Base Case scenario is 93.7 EUR. Compared to the current market price of 58.19 EUR, Bayer AG is Undervalued by 38%.

The Intrinsic Value is calculated as the average of the two valuation methods:

BAYN Intrinsic Value
Base Case
93.7 EUR
Undervaluation 38%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

BAYN Profitability Score
Profitability Due Diligence

Bayer AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Positive Operating Income
Positive Net Income
47/100
Profitability
Score

Bayer AG's profitability score is 47/100. The higher the profitability score, the more profitable the company is.

BAYN Solvency Score
Solvency Due Diligence

Bayer AG's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Average Interest Coverage
Low Altman Z-Score
Positive Net Debt
Low D/E
37/100
Solvency
Score

Bayer AG's solvency score is 37/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
62%
Gross Margin
15%
Operating Margin
9%
Net Margin
9%
FCF Margin
13%
ROE
6%
ROIC
Other

BAYN Capital Structure
Bayer AG

Market Capitalization 57.2B EUR
Total Debt 39.5B EUR
Minority Interest 195M EUR
Preferred Equity 0 EUR
Cash and Equivalents 4.4B EUR
Short-Term Investments 4.7B EUR
Enterprise Value 87.7B EUR

Wall St
Price Targets

BAYN Price Targets Summary
Bayer AG

Wall Street analysts forecast BAYN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BAYN is 76.46 EUR with a low forecast of 54.54 EUR and a high forecast of 111.3 EUR.

Lowest
Price Target
54.54 EUR
6% Downside
Average
Price Target
76.46 EUR
31% Upside
Highest
Price Target
111.3 EUR
91% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

BAYN Competitors
Bayer AG

BAYN Suppliers & Customers
Bayer AG

Bayer AG has 111 key suppliers from 11 countries and 20 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.

United States of America
50
Veeva Systems Inc
Health Care
Johnson & Johnson
Pharmaceuticals
Omnicom Group Inc
Media
E
E2open Parent Holdings Inc
Technology
Bristol-Myers Squibb Co
Pharmaceuticals
EnPro Industries Inc
Machinery
G
Ginkgo Bioworks Holdings Inc
Chemicals
Catalent Inc
Pharmaceuticals
Corteva Inc
Chemicals
Invitae Corp
Health Care
Merck & Co Inc
Pharmaceuticals
Scotts Miracle-Gro Co
Chemicals
Graphic Packaging Holding Co
Packaging
Avangrid Inc
Utilities
Huntsman Corp
Chemicals
Alteryx Inc
Technology
VistaGen Therapeutics Inc
Biotechnology
V
Vincerx Pharma Inc
Biotechnology
Precigen Inc
Biotechnology
Schrodinger Inc
Health Care
Yield10 Bioscience Inc
Biotechnology
Regenxbio Inc
Biotechnology
Arvinas Inc
Pharmaceuticals
Whole Earth Brands Inc
Food Products
P
Pyxis Oncology Inc
Biotechnology
Berkeley Lights Inc
Life Sciences Tools & Services
T
Thoughtworks Holding Inc
Technology
Progress Software Corp
Technology
Selecta Biosciences Inc
Biotechnology
Dare Bioscience Inc
Pharmaceuticals
Ultragenyx Pharmaceutical Inc
Biotechnology
Qumu Corp
Technology
Insignia Systems Inc
Media
Editas Medicine Inc
Biotechnology
Harvard Bioscience Inc
Life Sciences Tools & Services
Ionis Pharmaceuticals Inc
Biotechnology
ImmunoGen Inc
Biotechnology
Microsoft Corp
Technology
R
Recursion Pharmaceuticals Inc
Biotechnology
Sotherly Hotels Inc
Real Estate
L
Lantheus Holdings Inc
Health Care
Atara Biotherapeutics Inc
Biotechnology
Regeneron Pharmaceuticals Inc
Biotechnology
Simulations Plus Inc
Health Care
Syndax Pharmaceuticals Inc
Biotechnology
E
Energy Services Of America Corp
N/A
Gene Biotherapeutics Inc
Biotechnology
Mastermind Inc
Media
H
Hexion Holdings Corp
Chemicals
S
Seaport Calibre Materials Acquisition Corp
N/A
Suppliers Map

Bayer AG has 43 key customers from 8 countries and 7 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Customers Map

Shareholder Return

BAYN Price
Bayer AG

1M 1M
+15%
6M 6M
+10%
1Y 1Y
+13%
3Y 3Y
-17%
5Y 5Y
-27%
Annual Price Range
58.19
52w Low
47.415
52w High
66.74
Price Metrics
Average Annual Return -9.57%
Standard Deviation of Annual Returns 28.78%
Max Drawdown -56%
Shares Statistics
Market Capitalization 57.2B EUR
Shares Outstanding 982 424 100
Percentage of Shares Shorted
N/A

Company Profile

Bayer AG

Country

Germany

Industry

Pharmaceuticals

Market Cap

57.2B EUR

Dividend Yield

3.45%

Description

Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. The company is headquartered in Leverkusen, Nordrhein-Westfalen and currently employs 99,637 full-time employees. The firm's segments are Pharmaceuticals, Consumer Health, Crop Science. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The firm is focusing on their oncology platform for Targeted Alpha Therapies for treating prostate cancer. The Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds.

Contact

NORDRHEIN-WESTFALEN
Leverkusen
Kaiser-Wilhelm-Allee 1
+49214301.0
https://www.bayer.de/

IPO

1997-11-28

Employees

99 637

Officers

Chairman of Management Board, CEO & Chief Sustainability Officer
Mr. Werner Baumann
CFO & Member of Management Board
Mr. Wolfgang U. Nickl
Member of Management Board & Pres of the Consumer Health Division
Mr. Heiko W. J. Schipper
Head of the Pharmaceuticals Division & Member of the Board of Management
Mr. Stefan Oelrich
Chief Transformation & Talent Officer, Labor Director and Member of Management Board
Ms. Sarena S. Lin
Member of Management Board & Pres of the Crop Science Division
Mr. Rodrigo Santos
Show More
Head of Accounting and Head of Taxes
Mr. Bernd-Peter Bier
Head of Investor Relations
Mr. Oliver Maier
Head of Law, Patents & Compliance
Dr. Gabriel Harnier
Head of Communications, Gov. Relations and Corp. Brand
Mr. Michael Preuss
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one BAYN stock?

The intrinsic value of one BAYN stock under the Base Case scenario is 93.7 EUR.

Is BAYN stock undervalued or overvalued?

Compared to the current market price of 58.19 EUR, Bayer AG is Undervalued by 38%.